脓毒症相关心源性休克中肺动脉导管的早期有创血流动力学监测
该研究基于美国全国住院患者样本(2017年1月至2019年12月)进行回顾性分析,评估早期(入院2天内)使用肺动脉导管(PAC)对脓毒症相关心源性休克患者的影响。多因素logistic回归显示,在无心源性休克的脓毒症患者中,PAC组与非PAC组住院死亡率无差异(aOR=1.05,95%CI 0.82-1.35,P=0.691);而在脓毒症相关心源性休克患者中,早期使用PAC与住院死亡率降低独立相关(aOR=0.58,95%CI 0.46-0.72,P<0.001),并与机械循环支持使用增加相关(aOR=12.26,95%CI 9.37-16.03,P<0.001)。入院2天后使用PAC则与住院死亡率显著升高和机械循环支持使用减少相关。
要点
- 脓毒症相关心源性休克患者入院2天内使用PAC与住院死亡率降低独立相关(aOR=0.58,95%CI 0.46-0.72,P<0.001)。
- 无心源性休克的脓毒症患者中,PAC组与非PAC组住院死亡率无差异(aOR=1.05,95%CI 0.82-1.35,P=0.691)。
- 脓毒症相关心源性休克患者中,使用PAC与机械循环支持使用增加相关(aOR=12.26,95%CI 9.37-16.03,P<0.001)。
- 脓毒症相关心源性休克患者入院2天后使用PAC与住院死亡率显著升高和机械循环支持使用减少相关。
适用人群与场景
- 脓毒症相关心源性休克患者及无心源性休克的脓毒症患者,数据来源于美国全国住院患者样本(2017年1月至2019年12月)。
诊断标准与关键阈值
- 早期使用PAC定义为入院2天内使用肺动脉导管。
研究设计与关键结果
- 回顾性研究,使用美国全国住院患者样本(2017年1月至2019年12月)数据,评估早期(入院2天内)使用PAC与住院死亡率的关系。
- 无心源性休克的脓毒症患者中,PAC组与非PAC组住院死亡率无差异(aOR=1.05,95%CI 0.82-1.35,P=0.691)。
- 脓毒症相关心源性休克患者中,早期使用PAC与住院死亡率降低独立相关(aOR=0.58,95%CI 0.46-0.72,P<0.001)。
- 脓毒症相关心源性休克患者中,使用PAC与机械循环支持使用增加相关(aOR=12.26,95%CI 9.37-16.03,P<0.001)。
- 脓毒症相关心源性休克患者入院2天后使用PAC与住院死亡率显著升高和机械循环支持使用减少相关。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在脓毒症相关心源性休克患者中,早期(入院2天内)使用PAC可能与该人群住院死亡率降低相关;在无心源性休克的脓毒症患者中,使用PAC与住院死亡率无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Both sepsis-induced cardiomyopathy and worsening of preexisting cardiac disease can contribute to circulatory shock in septic patients. The early use of pulmonary artery catheter (PAC) could play a pivotal role in the management of sepsis-associated cardiogenic shock. In this study, we aimed to evaluate the impact of early invasive hemodynamic monitoring with PAC in patients with sepsis-associated cardiogenic shock. Method: We performed a retrospective study using the National Inpatient Sample data from January 2017 to December 2019. The early use of PAC was defined as the use of PAC within 2 days from the admission. We performed the multivariable logistic regression analysis to investigate the association between the early use of PAC and in-hospital mortality in patients with sepsis-associated cardiogenic shock and sepsis without cardiogenic shock, respectively. Results: There was no difference in in-hospital mortality between PAC and no PAC groups in sepsis without cardiogenic shock (adjusted odds ratio [aOR] = 1.05, 95% confidence interval [CI] = 0.82-1.35, P = 691). On the other hand, the early use of PAC was independently associated with lower in-hospital mortality in patients with sepsis-associated cardiogenic shock (aOR = 0.58, 95% confidence interval [CI] = 0.46-0.72, P < 0.001). The use of PAC was also associated with increased use of mechanical circulatory support in those with sepsis-associated cardiogenic shock (aOR = 12.26, 95% CI = 9.37-16.03, P < 0.001). For patients with sepsis-associated cardiogenic shock, the use of PAC after 2 days of admission was associated with significantly higher in-hospital mortality and decreased use of mechanical circulatory support. Conclusion: The use of pulmonary artery catheters in sepsis-associated cardiogenic shock was associated with significantly lower in-hospital mortality and increased use of mechanical circulatory supports in patients with sepsis-associated cardiogenic shock.
参考来源
- Sato R, Hasegawa D, Guo SC, et al. INVASIVE HEMODYNAMIC MONITORING WITH PULMONARY ARTERY CATHETER IN SEPSIS-ASSOCIATED CARDIOGENIC SHOCK. Shock. 2023. PMID: 38150363. doi:10.1097/SHK.0000000000002290
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。